Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS Hospital, Milan 20132, Italy.
Department of Medicine, Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
Endocr Rev. 2024 Sep 12;45(5):625-654. doi: 10.1210/endrev/bnae009.
The 6th International Conference, "Controversies in Vitamin D," was convened to discuss controversial topics, such as vitamin D metabolism, assessment, actions, and supplementation. Novel insights into vitamin D mechanisms of action suggest links with conditions that do not depend only on reduced solar exposure or diet intake and that can be detected with distinctive noncanonical vitamin D metabolites. Optimal 25-hydroxyvitamin D (25(OH)D) levels remain debated. Varying recommendations from different societies arise from evaluating different clinical or public health approaches. The lack of assay standardization also poses challenges in interpreting data from available studies, hindering rational data pooling and meta-analyses. Beyond the well-known skeletal features, interest in vitamin D's extraskeletal effects has led to clinical trials on cancer, cardiovascular risk, respiratory effects, autoimmune diseases, diabetes, and mortality. The initial negative results are likely due to enrollment of vitamin D-replete individuals. Subsequent post hoc analyses have suggested, nevertheless, potential benefits in reducing cancer incidence, autoimmune diseases, cardiovascular events, and diabetes. Oral administration of vitamin D is the preferred route. Parenteral administration is reserved for specific clinical situations. Cholecalciferol is favored due to safety and minimal monitoring requirements. Calcifediol may be used in certain conditions, while calcitriol should be limited to specific disorders in which the active metabolite is not readily produced in vivo. Further studies are needed to investigate vitamin D effects in relation to the different recommended 25(OH)D levels and the efficacy of the different supplementary formulations in achieving biochemical and clinical outcomes within the multifaced skeletal and extraskeletal potential effects of vitamin D.
第六届国际会议“维生素 D 争议”的召开旨在讨论一些有争议的话题,如维生素 D 的代谢、评估、作用和补充。对维生素 D 作用机制的新见解表明,其与仅依赖于减少阳光暴露或饮食摄入而无法检测到的独特非典型维生素 D 代谢物的条件有关。最佳的 25-羟维生素 D(25(OH)D)水平仍存在争议。不同协会提出的不同建议源于评估不同的临床或公共卫生方法。缺乏检测标准化也对解释现有研究数据提出了挑战,阻碍了合理的数据汇总和荟萃分析。除了众所周知的骨骼特征外,人们对维生素 D 的非骨骼作用的兴趣导致了癌症、心血管风险、呼吸影响、自身免疫性疾病、糖尿病和死亡率的临床试验。最初的阴性结果可能是由于招募了维生素 D 充足的个体。随后的事后分析表明,尽管如此,在降低癌症发病率、自身免疫性疾病、心血管事件和糖尿病方面仍可能存在潜在益处。口服维生素 D 是首选途径。肠外给药保留用于特定的临床情况。由于安全性和最小的监测要求,胆钙化醇是首选。在某些情况下可使用骨化二醇,而骨化三醇应限于体内不易产生活性代谢物的特定疾病。需要进一步研究以调查维生素 D 与不同推荐的 25(OH)D 水平的关系,以及不同补充配方在实现生化和临床结果方面的功效,以充分发挥维生素 D 的多方面骨骼和非骨骼潜在作用。